EA200970404A1 - Соединения, проявляющие активность в отношении св - Google Patents

Соединения, проявляющие активность в отношении св

Info

Publication number
EA200970404A1
EA200970404A1 EA200970404A EA200970404A EA200970404A1 EA 200970404 A1 EA200970404 A1 EA 200970404A1 EA 200970404 A EA200970404 A EA 200970404A EA 200970404 A EA200970404 A EA 200970404A EA 200970404 A1 EA200970404 A1 EA 200970404A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
respect
experiencing activity
experiencing
activity
Prior art date
Application number
EA200970404A
Other languages
English (en)
Other versions
EA015745B1 (ru
Inventor
Джон Менерт Шаус
Перри Кларк Хит
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200970404A1 publication Critical patent/EA200970404A1/ru
Publication of EA015745B1 publication Critical patent/EA015745B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Соединение и фармацевтические композиции формулыкоторые, благодаря способности блокировать рецепторы CBпо механизму обратного агонизма, пригодны для снижения массы тела у млекопитающих, лечения когнитивных нарушений, связанных с шизофренией, снижения возникшего в результате лечения увеличения веса, наблюдаемого при лечении антипсихотическими препаратами, и имеют повышенную биодоступность.
EA200970404A 2006-10-23 2007-10-22 Соединения, проявляющие активность в отношении св EA015745B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86254006P 2006-10-23 2006-10-23
PCT/US2007/082041 WO2008070305A2 (en) 2006-10-23 2007-10-22 1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as cbl' receptor modulator

Publications (2)

Publication Number Publication Date
EA200970404A1 true EA200970404A1 (ru) 2009-10-30
EA015745B1 EA015745B1 (ru) 2011-10-31

Family

ID=39386481

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200970405A EA015175B1 (ru) 2006-10-23 2007-10-22 Соединения, проявляющие активность в отношении рецептора св
EA200970404A EA015745B1 (ru) 2006-10-23 2007-10-22 Соединения, проявляющие активность в отношении св

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200970405A EA015175B1 (ru) 2006-10-23 2007-10-22 Соединения, проявляющие активность в отношении рецептора св

Country Status (23)

Country Link
US (2) US8168659B2 (ru)
EP (2) EP2094684B1 (ru)
JP (2) JP5331002B2 (ru)
KR (2) KR101088229B1 (ru)
CN (2) CN101528733B (ru)
AR (1) AR063497A1 (ru)
AT (1) ATE492543T1 (ru)
AU (1) AU2007329808B2 (ru)
BR (1) BRPI0717347A2 (ru)
CA (2) CA2667210C (ru)
CL (1) CL2007003002A1 (ru)
CY (1) CY1111140T1 (ru)
DE (1) DE602007011495D1 (ru)
DK (2) DK2094684T3 (ru)
EA (2) EA015175B1 (ru)
ES (2) ES2356025T3 (ru)
MX (2) MX2009004053A (ru)
PE (1) PE20080926A1 (ru)
PL (2) PL2094684T3 (ru)
PT (2) PT2094684E (ru)
SI (2) SI2094684T1 (ru)
TW (1) TW200825067A (ru)
WO (2) WO2008070305A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR063497A1 (es) * 2006-10-23 2009-01-28 Lilly Co Eli Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
MX2010011546A (es) * 2008-04-22 2010-11-09 Lilly Co Eli Compuestos de 1,5-difenil-pirrolidin-2-ona como ligandos de cb-1.
DK2280961T3 (da) 2008-04-22 2012-08-27 Lilly Co Eli 1,5-diphenyl-pyrrolidin-2-on-forbindelser som cb-1-ligander
WO2010057000A2 (en) * 2008-11-13 2010-05-20 The Trustees Of Columbia University In The City Of New York Neuraminidase inhibitors and uses thereof
CA2805091A1 (en) 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions comprising a homopathically potentized form of an antibody to human cannabinoid receptor
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2022132803A1 (en) * 2020-12-14 2022-06-23 The Board Of Trustees Of The Leland Stanford Junior University Cb2 receptor agonists
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
KR20060131908A (ko) 2004-02-19 2006-12-20 솔베이 파마슈티칼스 비. 브이 Ｃｂ1-길항 활성을 갖는 이미다졸린 유도체
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
WO2007020502A2 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof
AR063497A1 (es) * 2006-10-23 2009-01-28 Lilly Co Eli Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento

Also Published As

Publication number Publication date
CA2667210C (en) 2013-09-24
MX2009004053A (es) 2009-04-27
ATE492543T1 (de) 2011-01-15
US20100016375A1 (en) 2010-01-21
PT2094684E (pt) 2011-01-28
DK2094684T3 (da) 2011-03-14
AR063497A1 (es) 2009-01-28
KR20090069316A (ko) 2009-06-30
EA015175B1 (ru) 2011-06-30
WO2008070305A2 (en) 2008-06-12
JP2010507590A (ja) 2010-03-11
EA200970405A1 (ru) 2009-12-30
WO2008070306A3 (en) 2008-07-31
CN101528733A (zh) 2009-09-09
AU2007329808B2 (en) 2013-11-07
CL2007003002A1 (es) 2008-06-06
SI2099784T1 (sl) 2013-02-28
MX2009004054A (es) 2009-04-27
EP2094684B1 (en) 2010-12-22
JP5331001B2 (ja) 2013-10-30
EA015745B1 (ru) 2011-10-31
PT2099784E (pt) 2013-01-04
CA2667210A1 (en) 2008-06-12
CN101528732B (zh) 2013-04-03
CA2667372A1 (en) 2008-06-12
EP2099784B1 (en) 2012-12-12
JP5331002B2 (ja) 2013-10-30
WO2008070305A3 (en) 2008-08-28
TW200825067A (en) 2008-06-16
CN101528732A (zh) 2009-09-09
PL2099784T3 (pl) 2013-05-31
DK2099784T3 (da) 2013-01-14
CN101528733B (zh) 2013-10-16
US7998985B2 (en) 2011-08-16
EP2094684A2 (en) 2009-09-02
SI2094684T1 (sl) 2011-04-29
EP2099784A2 (en) 2009-09-16
US20090275618A1 (en) 2009-11-05
CA2667372C (en) 2013-09-03
KR101088236B1 (ko) 2011-11-30
DE602007011495D1 (de) 2011-02-03
PE20080926A1 (es) 2008-07-19
KR101088229B1 (ko) 2011-11-30
AU2007329807A1 (en) 2008-06-12
US8168659B2 (en) 2012-05-01
WO2008070306A2 (en) 2008-06-12
JP2010507589A (ja) 2010-03-11
PL2094684T3 (pl) 2011-05-31
ES2398388T3 (es) 2013-03-15
KR20090071613A (ko) 2009-07-01
CY1111140T1 (el) 2015-06-11
AU2007329808A1 (en) 2008-06-12
ES2356025T3 (es) 2011-04-04
BRPI0717347A2 (pt) 2014-01-14

Similar Documents

Publication Publication Date Title
EA200970404A1 (ru) Соединения, проявляющие активность в отношении св
EA201070169A1 (ru) 2,3-дигидробензо[1,4]диоксин-2-илметиловые производные в качестве альфа2с антагонистов для применения в лечении заболеваний перифирической центральной нервной системы
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
EA201300869A1 (ru) Морфинановые соединения
CR8919A (es) Analogos de tetrapeptidos
ME01532B (me) Jedinjenja
NO20083630L (no) Nye pyridinderivater
CY1115188T1 (el) Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl
UY30816A1 (es) Compuestos activos en proteina quinasa, composicionesconteniéndolos y plicaciones
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
ATE438633T1 (de) Benzo (d) isoxazol-3-yl-amin- verbindungen und deren verwendung als vanilloid-rezeptor liganden
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
CU24087B1 (es) Compuestos de carbazol
CR9677A (es) Derivados de pirrolo(2,3-b) piridina como inhibidores de proteina cinasa
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
EA200701114A1 (ru) Азоловые производные с антимускариновой активностью
CL2007002188A1 (es) Compuestos derivados de heteroarilaminas; procedimiento de preparacion; composicion farmceutica; y uso del compuesto para tratar el crecimiento celular anormal.
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
TW200942524A (en) Novel aminomethyl benzene derivatives
MA32505B1 (fr) 5-alcynyl-pyrimidines
CL2007003289A1 (es) Compuestos derivados de biciclocarboxiamida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades provocadas por la hiperactivacion del receptor vc1 como dolor, enfermedad de vejiga, inflam
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu
ATE481972T1 (de) Chinazolinon-derivate als vanilloid-antagonisten

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU